BDX Stock Forecast & Price Target

Becton Dickinson is attractive because its post-separation portfolio is broad, diversified, and defensively recurring, with more than 60% of sales in the United States and high consumables exposure across four units that collectively span a $70B TAM growing about 5%. The company’s Medical Essentials, Connected Care, Biopharma Systems, and Interventional franchises are supported by BD Excellence, which has driven about 8% plant productivity and continued margin expansion even while absorbing tariff pressure, while recent quarterly results showed $4,983M in revenue, all four segments beating expectations, and adj. EPS of $3.23. The outlook is further strengthened by disciplined capital allocation, including $2.2B of FY25 shareholder returns, a buyback priority, and the prospect that focused investment in higher-growth platforms can convert its durable core into steady low- to mid-single-digit revenue growth and high-single-digit EPS growth.

Becton Dickinson is viewed negatively because the separation of Biosciences and Diagnostics still carries execution risk, and the company may fail to hit post-deal financial targets while facing funding cuts, tariffs, China pressure, and broader inflation or supply-chain headwinds. Competition remains intense across Medical, Connected Care, Biopharma Systems, and Interventional, even as more than 60% of revenue comes from the United States, leaving results exposed to shifts in healthcare delivery and reimbursement. Although FY26 organic revenue is guided to the high end of low-single digits and adjusted EPS to $12.62-$12.72, those improvements are offset by a roughly 200 bps Alaris remediation drag in Q4, FY27 low-single-digit growth, and only modest margin leverage despite $1.7 billion of YTD free cash flow.